262 related articles for article (PubMed ID: 31169082)
21. Dipeptidyl Peptidase-4 Inhibitor-associated Bullous Pemphigoid: Recurrence with Epitope Spreading.
Takama H; Yoshida M; Izumi K; Yanagishita T; Muto J; Ohshima Y; Nishie W; Shimizu H; Akiyama M; Watanabe D
Acta Derm Venereol; 2018 Nov; 98(10):983-984. PubMed ID: 30085319
[No Abstract] [Full Text] [Related]
22. Bullous pemphigoid (BP) patients with selective IgG autoreactivity against BP230: Review of a rare but valuable cohort with impact on the comprehension of the pathogenesis of BP.
Ramcke T; Vicari E; Bolduan V; Enk A; Hadaschik E
J Dermatol Sci; 2022 Feb; 105(2):72-79. PubMed ID: 34930674
[TBL] [Abstract][Full Text] [Related]
23. Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors. A case series and analysis of cases reported in the Spanish pharmacovigilance database.
Reolid A; Muñoz-Aceituno E; Rodríguez-Jiménez P; González-Rojano E; Llamas-Velasco M; Fraga J; Daudén E
Int J Dermatol; 2020 Feb; 59(2):197-206. PubMed ID: 31605541
[TBL] [Abstract][Full Text] [Related]
24. Complement-independent blistering mechanisms in bullous pemphigoid.
Iwata H; Ujiie H
Exp Dermatol; 2017 Dec; 26(12):1235-1239. PubMed ID: 28418613
[TBL] [Abstract][Full Text] [Related]
25. Epitope-spreading phenomena in dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid.
García-Díez I; España A; Iranzo P
Br J Dermatol; 2019 May; 180(5):1267-1268. PubMed ID: 30675718
[No Abstract] [Full Text] [Related]
26. Three Cases of Bullous Pemphigoid Associated with Dipeptidyl Peptidase-4 Inhibitors - One due to Linagliptin.
Mendonça FM; Martín-Gutierrez FJ; Ríos-Martín JJ; Camacho-Martinez F
Dermatology; 2016; 232(2):249-53. PubMed ID: 26820308
[TBL] [Abstract][Full Text] [Related]
27. BPDAI and ABSIS correlate with serum anti-BP180 NC16A IgG but not with anti-BP230 IgG in patients with bullous pemphigoid.
Daneshpazhooh M; Ghiasi M; Lajevardi V; Nasiri N; Balighi K; Teimourpour A; Khosravi H; Saeidi V; Mahmoudi H; Chams-Davatchi C
Arch Dermatol Res; 2018 Apr; 310(3):255-259. PubMed ID: 29423547
[TBL] [Abstract][Full Text] [Related]
28. Gliptin-associated Bullous Pemphigoid and the Expression of Dipeptidyl Peptidase-4/CD26 in Bullous Pemphigoid.
Lindgren O; Varpuluoma O; Tuusa J; Ilonen J; Huilaja L; Kokkonen N; Tasanen K
Acta Derm Venereol; 2019 May; 99(6):602-609. PubMed ID: 30848289
[TBL] [Abstract][Full Text] [Related]
29. Levels of anti-BP180 NC16A IgE do not correlate with severity of disease in the early stages of bullous pemphigoid.
Bing L; Xiping Z; Li L; Jun P; Yi-Xia W; Min Y; Qing L; Qiu-Ning S; Hong-Zhong J; Ya-Gang Z
Arch Dermatol Res; 2015 Nov; 307(9):849-54. PubMed ID: 26404084
[TBL] [Abstract][Full Text] [Related]
30. Correlation of Serum Levels of IgE Autoantibodies Against BP180 With Bullous Pemphigoid Disease Activity.
van Beek N; Lüttmann N; Huebner F; Recke A; Karl I; Schulze FS; Zillikens D; Schmidt E
JAMA Dermatol; 2017 Jan; 153(1):30-38. PubMed ID: 27829102
[TBL] [Abstract][Full Text] [Related]
31. Relapse-associated autoantibodies to BP180 in a patient with anti-p200 pemphigoid.
Kasperkiewicz M; Hoppe U; Zillikens D; Schmidt E
Clin Exp Dermatol; 2010 Aug; 35(6):614-7. PubMed ID: 19874345
[TBL] [Abstract][Full Text] [Related]
32. Autoimmunity in bullous pemphigoid.
Wong MM; Giudice GJ; Fairley JA
G Ital Dermatol Venereol; 2009 Aug; 144(4):411-21. PubMed ID: 19755944
[TBL] [Abstract][Full Text] [Related]
33. Clinical and immunological profile of patients with dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid.
Bellinato F; Maurelli M; Schena D; Gisondi P; Girolomoni G
Ital J Dermatol Venerol; 2021 Aug; 156(4):455-459. PubMed ID: 32545941
[TBL] [Abstract][Full Text] [Related]
34. The significance of preclinical anti-BP180 autoantibodies.
Mai Y; Izumi K; Mai S; Ujiie H
Front Immunol; 2022; 13():963401. PubMed ID: 36003369
[TBL] [Abstract][Full Text] [Related]
35. A Cross-Sectional Study Comparing the Prevalence of Bullous Pemphigoid Autoantibodies in 275 Cases of Type II Diabetes Mellitus Treated With or Without Dipeptidyl Peptidase-IV Inhibitors.
Izumi K; Nishie W; Beniko M; Shimizu H
Front Immunol; 2019; 10():1439. PubMed ID: 31297116
[No Abstract] [Full Text] [Related]
36. From Molecular Insights to Clinical Perspectives in Drug-Associated Bullous Pemphigoid.
de Nicolas-Ruanes B; Ballester-Martinez A; Garcia-Mouronte E; Berna-Rico E; Azcarraga-Llobet C; Fernandez-Guarino M
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069109
[TBL] [Abstract][Full Text] [Related]
37. Patients with bullous pemphigoid and linear IgA disease show a dual IgA and IgG autoimmune response to BP180.
Kromminga A; Scheckenbach C; Georgi M; Hagel C; Arndt R; Christophers E; Bröcker EB; Zillikens D
J Autoimmun; 2000 Nov; 15(3):293-300. PubMed ID: 11040070
[TBL] [Abstract][Full Text] [Related]
38. Exploring mechanisms of IgE-mediated autoimmunity through the lens of bullous pemphigoid.
Messingham KN; Randall G; Fairley J
G Ital Dermatol Venereol; 2016 Apr; 151(2):186-97. PubMed ID: 26959553
[TBL] [Abstract][Full Text] [Related]
39. IgE autoantibodies against the intracellular domain of BP180.
Dresow SK; Sitaru C; Recke A; Oostingh GJ; Zillikens D; Gibbs BF
Br J Dermatol; 2009 Feb; 160(2):429-32. PubMed ID: 18808416
[TBL] [Abstract][Full Text] [Related]
40. Dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid showing positive autoantibody responses to multiple epitopes.
Kitao R; Fukumoto T; Hashimoto T; Izumi K; Jimbo H; Takemori C; Nishigori C
J Dermatol Sci; 2021 Sep; 103(3):190-192. PubMed ID: 34489165
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
